NASDAQ:CASI 延时15分钟

成交量

Yue Wu: Yue Wu was the founder of Crown Bioscience, Inc., founded in 2006, serving as President, CEO & Chief Scientific Officer from 2006 to 2017. Dr. Wu was the founder of Unimicro Technologies, Inc., founded in 2009, serving as Chief Operating Officer. Dr. Wu was the founder of Crown Bioscience International, founded in 2006, serving as President, Chief Executive & Strategy Officer from 2006 to 2017. Dr. Wu is the founder of Cothera Bioscience, Inc., founded in 2018, serving as President & Chief Executive Officer. Current jobs include Director at Scilex Pharmaceuticals, Inc. since 2019; Independent Director at Scilex Holding Co. since 2023; Independent Director at CASI Pharmaceuticals, Inc. since 2013; and Independent Director at Semnur Pharmaceuticals, Inc. starting in 2025. Former jobs include Independent Director at CASI Pharmaceuticals, Inc.; Independent Director at Sorrento Therapeutics, Inc.; Manager-Business Development & Strategic Planning at F. Hoffmann-La Roche Ltd.; Chief Operating Officer at Burrill LLC; Chief Business Officer at Starvax, Inc.; and Chief Business Officer at Starvax International, Inc. (China) from 2004 to 2006. Education includes an MBA and doctorate from the University of California, Berkeley; undergraduate degree from Fudan University; and graduate degree from the University of Illinois At Urbana Champaign.

Zhen Bo Su: Mr. Zhen Bo Su is an Independent Director at CASI Pharmaceuticals, Inc., a Managing Partner at Shenzhen Share Investment LP, a Partner at Guangzhou Redhill Capital Investment Management Co. , Ltd. and a Partner at Redhill Capital Investment Management Co. Ltd. He is on the Board of Directors at CASI Pharmaceuticals, Inc. and Shenzhen Share Investment LP. Mr. Su was previously employed as a Co-Founder by Chongqing TCR CURE Biopharma Technology Co., Ltd, an Executive Director by Genetron Holdings Ltd., an Executive Director by LIGHT VISION CO., LTD., an Executive Director by Meyer FSMP Hong Kong Ltd., an Executive Director by Polyrey Medical Tech (Suzhou) Co., Ltd., and an Executive Director by TCRCcure Biopharma Ltd. He received his undergraduate degree from Guangdong Medical University, a graduate degree from Sun Yat-Sen University and an MBA from The University of Chicago.

Thomas Folinsbee: Mr. Thomas Folinsbee, CFA, is an Independent Director at CASI Pharmaceuticals, Inc. and a Director-Business Development at Shanghai Alebund Pharmaceuticals Ltd. He is on the Board of Directors at CASI Pharmaceuticals, Inc. Mr. Folinsbee was previously employed as an Independent Director by Xynomic Pharmaceuticals Holdings, Inc., an Independent Director by Bison Capital Acquisition Corp., a Director-Corporate Development by 3SBio, Inc., and an Independent Director by Summit Healthcare Acquisition Corp. He also served on the board at Hisanaga Seisakusho Co. Ltd. He received his undergraduate degree from McGill University.

Xue Bo Zeng: Xue Bo Zeng currently works at Chiral Quest (Suzhou) Co., Ltd., as Director, Shanghai Model Organisms Center, Inc., as Director from 2022, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., as Non-Executive Director from 2022, Shandong Bestcomm Pharmaceutical Co., Ltd., as Director from 2017, CASI Pharmaceuticals, Inc., as Independent Director from 2023, Sunshine Lake Pharma Co., Ltd., as Non-Executive Director from 2024, and Hexie Zhuorui Zhuhai Investment Management Co. Ltd., as Vice President from 2020. Mr. Zeng also formerly worked at Shenzhen Investment Holdings Co., Ltd., as Deputy Director from 2015 to 2016, Hangzhou Sciwind Biosciences Co., Ltd., as Director, and IDG Capital, as Executive Director from 2010 to 2016. Mr. Zeng received his undergraduate degree in 2009 from Qinghai Nationalities University.

David A. Cory: David A. Cory is the founder. Mr. Cory was the founder of Eiger BioPharmaceuticals, Inc. (2008) and served as President, Chief Executive Officer & Director. Mr. Cory is also the founder of CoTherix, Inc. Mr. Cory is the Chief Executive Officer & Director at CASI Pharmaceuticals, Inc. since 2025. Former positions included Chief Executive Officer at DiObex, Inc. (2007-2008), President, Chief Executive Officer & Director at Eiger BioPharmaceuticals, Inc. (2009-2016), Chief Executive Officer & Director at LIB Therapeutics LLC (2023-2025), and Principal at The Upjohn Co., Glaxo Wellcome, Inc., and GlaxoSmithKline LLC. Education includes an MBA from the University of Maryland University College and an undergraduate degree from The James L. Winkle College of Pharmacy.

CASI制药公司